Showing 1641-1650 of 7024 results for "".
Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.What Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysDermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinInsights on Care for Skin of Color, Part 2
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-2/18185/Hilary Baldwin, MD and James Q. Del Rosso, DO continue their discussion with host Neal Bhatia, MD about managing skin of color. They address long-term management strategies and the need for cultural awareness.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futUpdates in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/updates-in-pediatric-dermatology/19733/2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuLasers and EBDs: Considerations for Ethnic Skin
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/lasers-and-ebds-considerations-for-ethnic-skin/20145/Monica Li, MD reviews evidence-based practices for using lasers, energy-based devices and minimally invasive procedures to manage benign dermatoses to treat patients with skin of color. She discusses the importance of engaging patients in appropriate pre- and post-treatment care to reduce potential